Cuorips Inc.

クオリプス

Industry: Pharmaceutical
Market: Growth
Accounting standards: Japanese GAAP
Consolidation basis: Consolidated

Notes

Consolidation basis
Consolidated / Since Mar 2024

Key metrics

Revenue(thousand JPY)

Mar 2023

38,278

Mar 2024

23,102

Mar 2025

175,205

Mar 2026

212,332

Operating profit(thousand JPY)

Mar 2023

-450,435

Mar 2024

-588,487

Mar 2025

-590,262

Mar 2026

-1,081,266

Operating profit margin(%)

Mar 2023

-1,176.75

Mar 2024

-2,547.34

Mar 2025

-336.9

Mar 2026

-509.23

Profit before tax(thousand JPY)

Mar 2023

-449,878

Mar 2024

-629,953

Mar 2025

-642,014

Mar 2026

-1,026,699

Profit(thousand JPY)

Mar 2023

-452,077

Mar 2024

-632,183

Mar 2025

-644,342

Mar 2026

-1,022,640

Total assets(thousand JPY)

Mar 2023

3,587,417

Mar 2024

6,184,738

Mar 2025

5,741,609

Mar 2026

5,123,122

Cash and cash equivalents(thousand JPY)

Mar 2023

2,941,896

Mar 2024

5,582,270

Mar 2025

4,793,824

Mar 2026

3,900,064

Cash flows from operating activities(thousand JPY)

Mar 2023

-401,612

Mar 2024

-451,060

Mar 2025

-812,616

Mar 2026

-1,059,895

Cash flows from investing activities(thousand JPY)

Mar 2023

-8,968

Mar 2024

-34,998

Mar 2025

-119,992

Mar 2026

-34,956

Cash flows from financing activities(thousand JPY)

Mar 2023

10,694

Mar 2024

3,125,418

Mar 2025

145,113

Mar 2026

204,205

Return on equity(-)

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Equity ratio(%)

Mar 2023

95.8

Mar 2024

96.6

Mar 2025

96.1

Mar 2026

91.6

Earnings per share(JPY per share)

Mar 2023

-79.9

Mar 2024

-85.86

Mar 2025

-80.52

Mar 2026

-124.54

Net assets per share(JPY per share)

Mar 2023

607.17

Mar 2024

751.28

Mar 2025

681.88

Mar 2026

568.01

Dividend per share(-)

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Payout ratio(-)

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Disclaimer

The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.

The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.